Rx Industry’s Economic Value Should Preclude Price Controls, Novartis Says
Executive Summary
The pharmaceutical industry is of "strategic value" to the U.S. economy and should not be jeopardized by instituting drug price controls, Novartis CEO Daniel Vasella, PhD, told the AARP International Forum on Prescription Drug Pricing Policy June 10 in Washington, D.C